Skip to main content
Back to Discussions

Meet the under-35s shaping the future of biotech

Healthcare
Global
Started September 12, 2026

Every year, MIT Technology Review puts together a list of some of the brightest and best young minds working across science and technology. Our 35 Innovators Under 35 are the ones to watch—people whose research and technical work stands to shape the future of their fields. This year, the list includes nine people who are…

Source Articles

Add Statement Analysis 0/5
Looking for a particular claim? Search all statements
🗳️ Join the conversation
10 statements to vote on • Your perspective shapes the analysis
📊 Progress to consensus analysis Needs 7+ participants and 20+ votes. Each statement joins once it has 3+ votes.
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Analysis can run once all three requirements are met.

Your votes count

No account needed. Your votes are saved and included in the consensus analysis. Create an account to keep a record of your votes.

CLAIM Posted by admin • Sep 12, 2026
Young biotech innovators should prioritize disease treatments that serve wealthy markets over rare diseases affecting poor populations.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Under-35s in biotech may prioritize profit over public health in their innovations.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
The achievements of young innovators in biotech should be widely celebrated to encourage further innovation.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Public funding for biotech should be allocated based on project promise, not on lists of celebrated names or ages.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Breakthrough biotech discoveries should be evaluated by their scientific merit and potential impact, not the age or background of the researcher.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Biotech education programs should heavily feature the work of young innovators to inspire future generations.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Public support for biotech research should include initiatives led by under-35s.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Regulatory agencies should streamline approval pathways for therapies developed by younger researchers to accelerate time-to-patient.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
The contributions of under-35s in biotech will likely lead to significant ethical dilemmas.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Sep 12, 2026
Biotech innovation leadership should reflect the demographic diversity of the populations whose health outcomes depend on new discoveries.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results

💡 How this works

  • • Add statements: Post claims or questions (10 to 500 characters).
  • • Vote: Agree, disagree or unsure on each statement.
  • • Respond: Add detailed arguments for or against, with evidence.
  • • Consensus: Once enough people take part, analysis shows opinion groups and where they agree.

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us